NDLI: Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.

Please wait, while we are loading the content...

Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Kelton, Christina M. L. Chang, Lenisa V. Guo, Jeff J. Yu, Yan Berry, Edmund A. Bian, Boyang Heaton, Pamela C.
Spatial Coverage	United States
Description	Author Affiliation: Kelton CM ( Carl H. Lindner College of Business, University of Cincinnati, 2925 Campus Green Drive, Cincinnati, OH, 45221, USA, chris.kelton@uc.edu.)
Abstract	BACKGROUND: The entry of generic drugs into markets previously monopolized by patented, branded drugs often represents large potential savings for healthcare payers in the USA. OBJECTIVES: Our objectives were to describe and explain the trends in drug reimbursement by public Medicaid programmes post-generic entry for as many drug markets and for as long a time period as possible. METHODS: The data were the Medicaid State Drug Utilization Data maintained by the Centers for Medicare and Medicaid Services. Quarterly utilization and expenditure data from 1991 to 2008 were extracted for 83 drugs, produced by 229 firms, that experienced initial generic entry between 1992 and 2004. A relative 'price' for a specific drug, firm and quarter was constructed as Medicaid reimbursement per unit (e.g. tablet, capsule or vial) divided by average reimbursement per unit for the branded drug the year before entry. Fixed-effects models controlling for time-, firm- and drug-specific differences were estimated to explain reimbursement. RESULTS: Twelve quarters after generic entry, 18 % of drugs had average per-unit reimbursement less than 50 % of the original branded-drug reimbursement. For each additional firm manufacturing the drug, reimbursement per unit, relative to the pre-generic-entry branded-drug reimbursement, was estimated to fall by 17 (p < 0.01) and 3 (p < 0.01) percentage points for generic and branded-drug companies, respectively. Each additional quarter post-generic entry brought a 2 (p < 0.01) percentage point drop in relative reimbursement. CONCLUSIONS: State Medicaid programmes generally have been able to obtain relief from high drug prices following patent expirations for many branded-drug medications by adjusting reimbursement following the expanded competition in the pharmaceutical market.
File Format	HTM / HTML
ISSN	11755652
Issue Number	2
Volume Number	12
e-ISSN	11791896
Journal	Applied Health Economics and Health Policy
Language	English
Publisher	Springer
Publisher Date	2014-04-01
Publisher Place	New Zealand (Aotearoa)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Health Services Discipline Public Health Cost Savings Statistics & Numerical Data Drug Costs Drugs, Generic Economics Health Expenditures Medicaid Trends Humans Models, Economic United States Journal Article
Content Type	Text
Resource Type	Article
Subject	Economics and Econometrics Health Policy

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.

Utilization, price, and spending trends for antidepressants in the US Medicaid Program.

Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009.

An explanatory model for state Medicaid per capita prescription drug expenditures.

Generic medicines: solutions for a sustainable drug market?

Projecting future drug expenditures--2012.

Volkswirtschaftliche Bedeutung von Generika.

Public drug expenditure in the Republic of Ireland.

Potential impact of pharmacist interventions to reduce cost for Medicare Part D beneficiaries.

Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.

Similar Documents

Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.

Utilization, price, and spending trends for antidepressants in the US Medicaid Program.

Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009.

An explanatory model for state Medicaid per capita prescription drug expenditures.

Generic medicines: solutions for a sustainable drug market?

Projecting future drug expenditures--2012.

Volkswirtschaftliche Bedeutung von Generika.

Public drug expenditure in the Republic of Ireland.

Potential impact of pharmacist interventions to reduce cost for Medicare Part D beneficiaries.

Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.